ABSTRACT Perfluorochemicals (PFCs) are known to provide a unique tool for controlled uptake and delivery of oxygen. We have characterized the effects of incremental oxygen delivery on cell viability of human ischemic cardiomyocytes using chemically inert PFCs as oxygen carrier. We have found that cell viability after prolonged ischemia depends on the dose of oxygen supplementation by oxygenated (ox) PFCs during reoxygenation. Although reoxygenation with the transient addition of oxPFCs in high concentrations (2250 M O 2 in 0.4 M PFCs) results in decreased cell viability compared with normoxic reoxygenation, cell survival increases by 30 Ϯ 4% after reoxygenation with moderate oxPFC concentrations (750 M O 2 in 0.1 M PFCs). Immunoblot analysis revealed that oxPFC-supplemented reoxygenation causes marked (16-fold) deactivation of death-associated protein kinase (DAPK) signaling an increase in mitochondrial membrane potential and a decreased steady-state level of superoxide by 19 Ϯ 3%. Reoxygenation with oxPFCs is further responsible for a 2-fold activation of AMP-activated protein kinase (AMPK) signaling an inadequate ATP supply by oxidative phosphorylation during reoxygenation. Addition of oxPFCs stabilizes both hypoxia-inducible factor (HIF) 1-␣ and 2-␣ during reoxygenation. Overall, these results indicate that moderate doses of oxPFCs can improve cell survival during reoxygenation, causing deactivation of DAPK, up-regulation of AMPK, and HIF1-␣ and 2-␣ stabilization. These effects of oxPFCs are dose-dependent, and they lead to a stabilization of the mitochondrial membrane potential, decreased steady-state levels of superoxide, and pacification of mitochondrial activity.
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The only proven way of salvaging ischemic tissue from cell death and impaired function today is early reperfusion. An end-link between reperfusion and cell viability is obviously cellular respiration in the mitochondrion. Mitochondria determine the energy metabolism of cardiomyocytes, because they produce more than 90% of the energy for the heart by oxidative phosphorylation (Barth et al., 1992) . Oxygen, the final electron acceptor in oxidative phosphorylation, maintains ATP synthesis in the inner membrane of the mitochondrion. In contrast, oxidative phosphorylation is a central site of reactive oxygen species production in the heart (Cai and Jones, 1998; Chandel et al., 2000; Yellon and Hausenloy, 2007) that may induce irreversible cellular damage and cell death (Davies, 1995) . Therefore, mitochondria have been recognized as central integration site at the crossroads of either cell survival or cell death (Murphy, 2004) . Alterations of oxidative phosphorylation in the mitochondrion have a key function in cardiomyocyte survival after ischemia/reperfusion. Accordingly, opposite effects of oxygen delivery during reperfusion and increased ATP availability have been reported, including increased cell viability but also increased apoptosis (Weiss et al., 2003) . These data raise the question of how the concept of normoxic reperfusion can be improved considering the fact that it triggers apoptosis.
Proapoptotic death-associated protein kinase (DAPK) is activated early during apoptosis (Schumacher et al., 2002a) , and its inhibition is protective after ischemia of the brain (Velentza et al., 2003) . It has been previously shown that DAPK is activated in human neuroblastoma cells by mitochondrial respiratory chain inhibitors that induce a decrease in the mitochondrial membrane potential and an increased steady-state level of superoxide (Shang et al., 2005) . However, it is unclear, whether oxygen can influence DAPK expression by changing the mitochondrial membrane potential or by increasing superoxide production.
Antiapoptotic AMP-activated protein kinase (AMPK) serves as an indicator of ATP availability in cells, detecting changes in the AMP:ATP ratio and signaling an inadequate ATP supply by oxidative phosphorylation (Hardie et al., 1998; Baron et al., 2005) . AMPK initiates a metabolic stress response that protects human cardiomyocytes against cell death (Spector et al., 2007) , but it has never been shown whether AMPK activity is affected by an gradual increase in oxygen concentration.
HIF1-␣ and 2-␣ are both known to be expressed in ischemic cardiomyocytes (Jü rgensen et al., 2004) , and stabilization of HIF1-␣ is known to be a cardiac survival factor during hypoxia (Lee et al., 2000) . However, it is unclear whether factors other than NO production by inducible nitric-oxide synthase mimic a hypoxic response under normoxia and could stabilize HIF during reoxygenation (Sandau et al., 2001) .
Chemically inert perfluorochemicals (PFCs) provide a unique tool for controlled delivery of oxygen (Rafikova et al., 2004) . Perfluorochemicals possess a high oxygen-dissolving capacity that follows Henry's law, leading to oxygen solubility that is directly proportional to oxygen partial pressure. As a result, oxygen can be extracted rapidly and extensively from PFCs (Riess, 2005) . Determining the conditions under which oxygen delivery by PFCs improves survival of ischemic cells and thereby preventing apoptosis in the surviving ischemic cells could result in an optimized regime of oxygen delivery during reperfusion.
Therefore, the aim of this study was to characterize the effects of delivering different dosing regimes of oxygenated (ox) PFCs with regard to changes in cell viability, oxidative phosphorylation, mitochondrial membrane potential, and superoxide production, and in particular to evaluate of the role of DAPK, AMPK, and HIF1-␣ and 2-␣ during reoxygenation.
Materials and Methods
Materials. Acridine orange was from Difco-BD Biosciences (Sparks, MD). Albumin bovine fraction V (BSA), bisbenzimide Hoechst 33342, collagenase VII, diethyldithiocarbamate, HEPES, lucigenin, phenylmethylsulfonyl fluoride, protease inhibitor cocktail, and Triton X-100 were purchased from Sigma-Aldrich (Steinheim, Germany). Enliten ATP assay system was from Promega (Madison, WI). KH 2 PO 4 was bought from Fluka (Buchs, Switzerland), and tetrabutylammonium bisulfate was obtained from Merck (Darmstadt, Germany). MitoTracker Red 7513 (chloromethyl-X-rosamine) was bought from Invitrogen (Carlsbad, CA), perfluorooctyl bromide from ABCR (Karlsruhe, Germany), and propidium iodide from BD Biosciences Pharmingen (Santiago, CA). Smooth muscle growth medium was purchased from PromoCell (Heidelberg, Germany), and perchloric acid was from Roche, Mannheim, Germany. Anti-HIF1-␣ antibody was obtained from Cell Signaling Technology (Beverly, MA) and anti-HIF2-␣ antibody was from Novus Biologicals, Inc. (Littleton, CO). Anti-phospho-AMPK-␣ 1 -Thr-172 and anti-AMPK-␣ antibodies were obtained from Cell Signaling Technology Inc. Anti-cardiac troponin I antibody was obtained from Accurate Chemical & Scientific (Westbury, NY) and anti-phospho-DAPK-Ser-308 antibody from Sigma-Aldrich (St. Louis, MO). Anti-DAPK was obtained from BD Biosciences Transduction Laboratories (Lexington, KY), and anti-manganese superoxide dismutase (MnSOD) antibody was obtained from Millipore Corporation (Billerica, MA).
Culture of Human Cardiomyocytes. Monolayer cultures of human cardiomyocytes were prepared by modifying the method of Merante et al. (1998) . In brief, heart tissue from the right atrium was obtained from male Caucasian patients with an average age of 76 years undergoing cardiovascular bypass surgery. The tissue was carefully dissected and further softened by digestion with 0.1% collagenase VII. Tissue specimens were washed in PBS and cultured in smooth muscle growth medium (PromoCell). After outgrowth of cells, cardiomyocyte colonies were transferred to new culture dishes. Cultures exhibiting Ͼ95% purity, as assessed by visual monitoring for rod-shaped cells and by fluorescent monoclonal antibody staining for troponin I during the first two passages, were used for subsequent studies.
Model of Hypoxia and Reoxygenation. Ischemia was mimicked by exposing cardiomyocytes (seeding density 3000 cells/cm 2 ) to a low-oxygen atmosphere (pO 2 Ͻ 40 mm Hg). Cardiomyocytes showed the most pronounced decrease of cell viability after increasing the period of hypoxia to 12 h. Hypoxia was maintained within the cell culture incubator by continuous infusion with a mixture of 95% N 2 /5% CO 2 in an airtight chamber for a period of 12 h before reoxygenation. Just before reoxygenation, pure perfluorooctyl bromide was ventilated with 100% carbogen (95% oxygen, 5% carbon dioxide) and was kept in an airtight vessel. Cardiomyocytes were reoxygenated with different doses of 100% perfluorooctyl bromide that were added to the cell medium. Because of its high density and its highly hydrophobic nature perfluorooctyl bromide formed a film over the cardiomyocyte monolayer in the cell culture dishes. This perfluorooctyl bromide film was separated from the normoxic atmosphere by the overlying cell medium. Perfluorooctyl bromide was removed after 10 min, and dishes were incubated for additional 1, 3, and 6 h in normoxia (pO 2 ϭ 150 mm Hg), 5% CO 2 , and humidified atmosphere within the cell culture incubator. Each sample was run with a control that received reoxygenation entirely at normoxic conditions. Volumetric Dosing of Perfluorooctyl Bromide. Oxygen solubility of 50 vol.% means that 1 volume of oxygen is dissolved in 2 volumes of perfluorooctyl bromide when 100% perfluorooctyl bromide is flushed with Ն95% oxygen for 5 min at room temperature (Riess, 2005) . The oxygen-carrying capacity of the perfluorooctyl bromide-supplemented cell medium obeys Henry's law of partial
. We added 500 and 2000 mol ⅐ l Ϫ1 oxygen to the already present 250 mol ⅐ l Ϫ1 oxygen in the cell culture medium. Because 22.4 liters of oxygen make 1 mol, 1 mmol ⅐ l Ϫ1 oxygen equals approximately 25 l of oxygen per milliliter of cells. Therefore, we added 18.75, 37.5, and 150 l of oxygen dissolved in 39.5, 75, and 300 l of oxPFCs in 3 ml of medium to cardiomyocytes cultured in a 60-mm dish (21.5 cm 2 ). When we applied 6.25, 12.5, and 50 l of oxygen per ml of cell medium, we increased the pO 2 to superphysiological levels of 160, 320, and 1300 mm Hg. These oxygen levels of the cell medium were greater than the arterial plasma oxygen concentration (3 l of oxygen per ml of plasma). The increase of oxygen in the cell culture medium was verified with a GMH 3610 analyzer (Greisinger Electronics, Regenstauf, Germany) for dissolved oxygen.
Measurement of Lactate Dehydrogenase. Lactate dehydrogenase (LDH) activity was measured in culture medium 6 h after reoxygenation. LDH was analyzed with the International Federation of Clinical Chemistry-recommended method (Schumann et al., 2002) using an LDH International Federation of Clinical Chemistry enzymatic reagent kit from Rolf Greiner BioChemica (Flacht, Germany). In brief, oxidation of lactate to pyruvate by LDH was measured as rate of increase in absorbance at 340 nm at 37°C.
Cell Viability Staining. Cell viability was analyzed by fluorescent staining as reported by Foglieni et al. (2001) . In brief, we used a triple dye combination of acridine orange, Hoechst 33342, and propidium iodide that visualizes all cell viability states simultaneously on the basis of nuclear and cytoplasmatic signals. Consecutively, cardiomyocytes were incubated in 20 M Hoechst 33342 for 20 min, in 0.67 nM acridine orange for 10 min and in 3 nM propidium iodide for 5 min at 37°C. Before and after each staining step, cells were washed with PBS. After fluorescent staining, cardiomyocytes were visualized with an Axioplan 2 imaging fluorescence microscopy under a long-pass fluorescein isothiocyanate filter from Zeiss (Goettingen, Germany). Healthy cells showed green colored cytoplasms; early apoptotic cells dark rust-yellow cytoplasms; necrotic cells showed orange cytoplasms. Axiovision 3.1 software and KS 300 3.0 software, both from Carl Zeiss (Goettingen, Germany), were used for quantification. 
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Mitochondrial Membrane Potential Visualization. Mitochondrial potential was assessed by the fluorescent dye MitoTracker Red 7513 (reduced chloromethyl-X-rosamine) as described previously by Gurevich et al. (2001) . In brief, cardiomyocytes were incubated in cell medium supplemented with 0.5 M chloromethyl-X-rosamine for 45 min within the cell culture incubator. Cells were fixed in 3.7% formalin for 15 min and in ice-cold acetone for 5 min. Before and after each staining step, cells were washed intensely with PBS. Axiovision 3.1 software and KS 300 3.0 software, both obtained from Carl Zeiss, were used for quantification.
Western Blot Analysis. Cardiomyocytes were washed and scraped off in ice-cold PBS supplemented with 1‰ protease inhibitor cocktail and 1 mM phenylmethylsulfonyl fluoride. The cells were centrifuged for 10 min at 220g, and then they were lysed using the MEM-PER eukaryotic membrane protein extraction kit from Pierce Chemical (Rockford, IL), according to the manufacturer's instructions. The lysate was centrifuged for 10 min at 10,000g at 4°C. From the clear supernatants, protein concentration was determined by the Bio-Rad protein assay kit (Bio-Rad, Munich, Germany) using BSA as control. Protein aliquots were boiled for 3 min in 2ϫ loading buffer and separated by electrophoresis on 7.5% SDS-polyacrylamide gel electrophoresis. Proteins were blotted onto polyvinylidene fluoride membranes (Millipore, Schwalbach, Germany), and then they were immunoblotted overnight with the indicated primary antibody followed by secondary antibody conjugated with alkaline phosphatase. The CDP-Star Reagent from New England Biolabs (Beverly, MA) was used for detection.
Superoxide Chemiluminescence. Superoxide production was analyzed by lucigenin chemiluminescence. In brief, after incubating cardiomyocytes with 50 mM diethyldithiocarbamate for 10 min (Omar et al., 1991) , cells were analyzed in HEPES buffer containing lucigenin that emits light on reduction of superoxide (Pagano et al., 1995) . Chemiluminescence was determined after a 2-s delay for 20 min, integrated over a 30-s period, and repeated every 2 min using a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA).
Immunohistochemistry. Consecutively, cardiomyocytes were incubated in 1% formalin at 4°C overnight, in 0.2% Triton X-100 for 5 min, blocked in 5% BSA for 1 h, and finally stained in 5% BSA with the indicated primary antibody (1:25) for 1 h and fluorescencelabeled secondary antibody (1:200) for 4 h. Before and after each staining step, cells were washed with PBS. After fluorescent staining, cardiomyocytes were visualized with an Axioplan 2 imaging fluorescence microscopy under a fluorescein isothiocyanate filter from Carl Zeiss. Axiovision 3.1 software and KS 300 3.0 software, both from Carl Zeiss, were used for quantification. ATP Determination. ATP was measured by the luciferin/luciferase method with a chemiluminescence kit (Promega) following the manufacturer's protocol. Chemiluminescence was determined in a TD-20/20 luminometer (Turner Designs), and data were analyzed in Excel (Microsoft, Redmond, WA). Alternatively, ATP was extracted from cardiomyocytes after reoxygenation treatment, separated by high-performance liquid chromatography, and quantified as described by Matoba et al. (1999) .
Statistical Analysis. Data are normalized for the amount of protein or number of cells engaged. All experiments were repeated at least three times. Data are given as percentage from normoxic value, which was set at 100%, and they are presented as mean Ϯ S.E. Comparisons were made using unpaired Student's t test or one-way analysis of variance when appropriate. Results were considered to be significantly different when P Ͻ 0.05. , we investigated the effect of supplemental oxygen delivery on cell viability during reoxygenation (Fig. 3) . Ischemic cells show a significant increase in cell viability (Ϸ 30% at 1 and 3 h and Ϸ20% at 6 h; P Ͻ 0.05), when O 2 concentrations were elevated transiently to 750 M O 2 dissolved in 0.1 M PFCs (Fig. 4) . No further increase was seen (Fig.  5) . On the contrary, ischemic cardiomyocytes reoxygenated with 2250 M O 2 in 0.4 M PFCs showed a significant decrease in cell viability (Ϸ40% at 3 h and Ϸ100% at 6 h; P Ͻ 0.05).
Results

Dosing
Deactivation of DAPK by Moderate Doses of oxPFCs during Reoxygenation. An increase in mitochondrial membrane potential after reoxygenation with addition of moderate concentrations of oxPFCs (750 M O 2 in 0.1 M PFCs) compared with normoxic reoxygenation seemed to be mediated by phosphorylation, and, consequently, by deactivation of DAPK. As shown in Fig. 6A , phosphorylated DAPK (pDAPK) was found almost at background level at normoxia (250 M O 2 ) and maximal after addition of 750 M O 2 in a moderate dosage of oxPFCs (P Ͻ 0.05). In contrast to this finding, DAPK phosphorylation did not increase significantly, when ischemic cardiomyocytes were exposed to 2250 M O 2 by a high dosage of oxPFCs (Fig. 6B) .
Stabilization of Mitochondrial Membrane Potential after oxPFC-Supplemented Reoxygenation. After normoxic reoxygenation (250 M O 2 ), a loss of mitochondrial membrane potential occurred as redistribution of the fluorochrome chloromethyl-X-rosamine from mitochondria to cytosol (Fig. 7A) . When cardiomyocytes were exposed to oxPFCs in moderate concentrations (750 M O 2 in 0.1 M PFCs), mitochondrial membrane potential stabilized and cardiomyocytes displayed a mitochondrion-selective fluorochrome staining (Fig.  6B ). An increase in mitochondrial membrane potential as well as a diminished loss of mitochondrial membrane potential was observed, when O 2 concentrations were elevated to 750 M O 2 by 0.1 M oxPFCs (Fig. 7C) . Six hours after O 2 concentrations were moderately elevated, the stabilization of the mitochondrial membrane potential was significant (Ϸ40%; P Ͻ 0.01) compared with normoxic reoxygenation. Dosing Regime of oxPFCs Affects Superoxide Production of Hypoxic Cardiomyocytes after Reoxygenation. The role of reoxygenation on superoxide production in hypoxic cardiomyocytes was investigated by measuring superoxide chemiluminescence after cardiomyocytes were ex- Figure 8A shows an immediate decrease in superoxide production, when O 2 concentrations were elevated transiently to 750 M O 2 . This decrease in superoxide production became significant after 3 h (Ϸ15% at 3 h and Ϸ20% at 6 h; P Ͻ 0.05) compared with normoxic reoxygenation. This decrease disappeared when hypoxic cardiomyocytes were reoxygenated with 2250 M O 2 in 0.4 M PFCs (Fig. 8B) . Hypoxic cardiomyocytes reoxygenated with a concentration of 2250 M O 2 showed a cumulative increase in superoxide production that became significant at 6 h (Ϸ50%; P Ͻ 0.05).
Mitochondrial Manganese Superoxide Dismutase Expression Decreases after Reoxygenation with Addition of oxPFCs in Moderate Concentrations. After reoxygenation applying 750 M O 2 in 0.1 M PFCs, mitochondrial MnSOD expression decreased significantly in comparison with normoxic reoxygenation (Ϸ26%; P Ͻ 0.05). When ischemic cardiomyocytes were reoxygenated with hyperoxic oxygen concentrations of 2250 M O 2 , MnSOD expression was increased (Ϸ154%; P Ͻ 0.05; Fig. 9 ) compared with normoxic reoxygenation.
Activation of AMPK after Moderate Doses of oxPFCs during Reoxygenation. The contribution of ATP generation on myocardial cell survival was tested by measuring AMPK activation, after exposing hypoxic cardiomyocytes transiently to oxPFCs in moderate concentrations (750 M O 2 in 0.1 M PFCs), and in toxic concentrations (2250 M O 2 in 0.4 M PFCs), or entirely to normoxic reoxygenation. Figure 10A shows that AMPK activation increased significantly (Ϸ2-fold; P Ͻ 0.01) after treatment of ischemic cardiomyocytes with oxPFCs in moderate concentrations (750 M O 2 ). However, oxPFCs (0.4 M) delivering oxygen in the toxic concentration of 2250 M O 2 did not increase but decreased AMPK activation significantly (Ϸ30%; P Ͻ 0.01), compared with normoxic reoxygenation (Fig. 10B) .
Based on the results of AMPK activation, we investigated whether the observed increase of AMPK activation with oxPFCs in moderate concentrations (750 M O 2 in 0.1 M PFCs) correlated with changes in cellular metabolism, compared with normoxic reoxygenation. We detected a small (Ϸ15%) but significant (P Ͻ 0.05) decrease in ATP content of cardiomyocytes after transient exposure to moderate concentrations of oxPFCs delivering 750 M O 2 .
Moderate Doses of oxPFCs during Reoxygenation Stabilize HIF1-␣ and HIF2-␣. We investigated whether a transient treatment of ischemic cardiomyocytes with hyperoxia induced a change in HIF1-␣ and HIF2-␣ stabilization compared with normoxic reoxygenation (250 M O 2 ). One hour after reoxygenation with a brief hyperoxia of 750 M O 2 , cardiomyocytes showed a weak HIF1-␣ expression signal (data not shown) that became prominent 3 h after reoxygenation with 750 M O 2 . Three hours after the oxygen concentration was elevated transiently to 750 M O 2 , ischemic cardiomyocytes showed a significant increase in HIF1-␣ stabilization (Ϸ45%; P Ͻ 0.05), as shown in Fig. 11A . This increase in HIF1-␣ stabilization disappeared 6 h after reoxygenation with 750 M O 2 , when the HIF1-␣ signal was not visible any longer. A particularly intense signal was obtained for HIF2-␣ after applying 750 M O 2 (Ϸ130%; P Ͻ 0.05), as shown in Fig. 11B . However, when ischemic cardiomyocytes were reoxygenated with the higher oxygen concentration of 2250 M O 2 , HIF1-␣ stabilization was not detectable at any time (data not shown).
Discussion
In the late 1980s, administration of oxygen using a perfluorochemical carrier was reported to result in a significant and sustained reduction in myocardial infarct size when delivered via the intracoronary route (Forman et al., 1991) , but further studies using different administration routes and carrier doses resulted in conflicting data on infarct reduction (Wall et al., 1994) . Recent studies using intracoronary oxygen perfusion with an aqueous oxygen solution have been reported to reduce infarct size and to improve myocardial contractility (Glazier, 2005) . Although promising, reperfusion strategies that supplement oxygen require fine-tuning to gain the desired cardioprotective effect and to limit toxic side effects. So far, it has never been specifically addressed how reoxygenation regimes differing in oxygen concentrations influence cell viability in ischemic cardiomyocytes.
We have found that the cell viability of human cardiomyocytes after prolonged ischemia depends on the regime of reoxygenation. Although reoxygenation with oxPFCs in high concentrations results in decreased cell viability compared with reoxygenation at normoxic conditions, reoxygenation with oxPFCs in moderate concentrations improves cell survival significantly by reducing necrosis and apoptosis. Our experiments show that the regenerative effect of oxPFC is a dose-dependent oxygen effect, whereas addition of PFCs alone had no effect on cell survival.
Proapoptotic DAPK has been suggested to serve as a sensor of mitochondrial membrane potential because mitochondrial respiratory chain inhibitors cause DAPK activation by decreasing mitochondrial membrane potential and increasing steady-state levels of superoxide (Shang et al., 2005) . Furthermore, DAPK plays an important role during the recovery phase after brain injury (Schumacher et al., 2002b) , and it has been shown that a selective DAPK inhibitor is neuroprotective in a model of brain ischemia (Shamloo et al., 2005) . We show that an increase in mitochondrial membrane potential after reoxygenation with moderate doses of oxPFCs may cause deactivation of DAPK, but normoxic reoxygenation does not alter DAPK, although this result is methodically limited by a change of cellular milieu by the fluorescent dye chloromethyl-X-rosamine. Toxic doses of oxPFCs lead to an increase in apoptosis and reduced viability of cardiomyocytes, and they do not deactivate DAPK. Thus, the dosing regime of oxygen is an important modulator of cell viability during reoxygenation.
In addition, our experiments show that the superoxide production of human cardiomyocytes after hypoxia depends on the regime of reoxygenation. Reoxygenation with toxic doses of oxPFCs results in a cumulative increase in superoxide production compared with normoxic reoxygenation. However, moderate doses of oxPFCs lead to a decrease in steady-state levels of superoxide. Our results underscore the "oxygen paradox," the mitochondrial electron-transport chain of higher eukaryotic aerobic organisms generates superoxide that seems to be responsible for oxygen toxicity (Davies, 1995) .
MnSOD is the principal antioxidant enzyme located in the mitochondrial matrix (Muller et al., 2004 ) that detoxifies mitochondrial superoxide into hydrogen peroxide. We show that MnSOD expression decreases after reoxygenation with oxPFCs in moderate concentrations. As mitochondrial superoxide is formed during oxidative phosphorylation from the mitochondrial electron transport chain (Babior et al., 1973) , the decrease in MnSOD expression implies a decrease in oxidative phosphorylation and superoxide production, underscoring the pacifying effect of moderate doses of oxPFCs on mitochondrial activity.
AMPK adjusts the cardiac energy metabolism to ischemia (Xing et al., 2003) , and it prevents postischemic cell death (Russell et al., 2004) . We show that AMPK activation increases after reoxygenation of ischemic cardiomyocytes using moderate doses of oxPFCs compared with normoxic reoxygenation. In addition, we observed a decrease in cellular ATP content with moderate doses of oxPFCs. Our findings corroborate previous findings that AMPK serves as an indicator of ATP availability in cells, detecting changes in the AMP:ATP ratio and signaling an inadequate ATP supply by oxidative phosphorylation (Hardie et al., 1998; Baron et al., 2005) . Reoxygenation with high doses of oxPFCs does not increase but rather decreases AMPK activation, indicating that toxic oxygen doses of oxPFCs may unhinge the protective capacity of antiapoptotic AMPK, leading eventually to necrosis and apoptosis.
We have demonstrated a dose-dependent effect of oxygen on stabilization of HIF1-␣ and HIF2-␣ in ischemic cardiomyocytes during reoxygenation. We were able to show a regenerative effect of moderate doses of oxPFCs that is lost when the dose of oxPFC is further increased. Although reoxygenation with oxygen in moderate concentrations (750 M O 2 ) increases HIF1-␣ and HIF2-␣ stabilization, compared with reoxygenation at normoxic conditions, reoxygenation with oxygen in higher concentrations (2250 M O 2 ) has no effect on HIF stabilization.
In conclusion, we report for the first time that treatment of ischemic cardiomyocytes with oxPFCs in moderate concentrations results in improved cell viability by stabilization of the mitochondrial membrane potential and reducing steadystate levels of superoxide in an in vitro model of ischemia and reperfusion. The gain in mitochondrial membrane potential is consistent with the pattern of increased AMPK expression after reoxygenation with moderate doses of oxPFCs, which signals a reduced rate of oxidative phosphorylation. DAPK senses an increase in mitochondrial membrane potential mediated by reduced steady-state levels of superoxide and becomes deactivated. We propose that increased viability of ischemic cardiomyocytes results from a pacifying effect of moderate doses of oxPFCs on the mitochondrial activity, superoxide steady-state levels and the stabilizing effect on HIF1-␣ and HIF2-␣ during reoxygenation. We propose that HIF1-␣ and HIF2-␣ stabilization could mediate a protective effect on ischemic cardiomyocytes during reperfusion. Accordingly, reperfusion strategies may offer advantages over conventional normoxic reperfusion when applying optimal oxygen concentrations to the ischemic myocardium.
